1-Aminomethyl SAR in a novel series of flavagline-inspired eIF4A inhibitors: Effects of amine substitution on cell potency and in vitro PK properties.


Journal

Bioorganic & medicinal chemistry letters
ISSN: 1464-3405
Titre abrégé: Bioorg Med Chem Lett
Pays: England
ID NLM: 9107377

Informations de publication

Date de publication:
01 09 2021
Historique:
received: 12 02 2021
revised: 02 05 2021
accepted: 08 05 2021
entrez: 6 8 2021
pubmed: 7 8 2021
medline: 5 1 2022
Statut: ppublish

Résumé

Flavaglines such as silvestrol (1) and rocaglamide (2) constitute an interesting class of natural products with promising anticancer activities. Their mode of action is based on inhibition of eukaryotic initiation factor 4A (eIF4A) dependent translation through formation of a stable ternary complex with eIF4A and mRNA, thus blocking ribosome scanning. Herein we describe initial SAR studies in a novel series of 1-aminomethyl substituted flavagline-inspired eIF4A inhibitors. We discovered that a variety of N-substitutions at the 1-aminomethyl group are tolerated, making this position pertinent for property and ADME profile tuning. The findings presented herein are relevant to future drug design efforts towards novel eIF4A inhibitors with drug-like properties.

Identifiants

pubmed: 34353608
pii: S0960-894X(21)00337-1
doi: 10.1016/j.bmcl.2021.128111
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Benzofurans 0
Biological Products 0
Triterpenes 0
silvestrol 0
rocaglamide 84573-16-0
Eukaryotic Initiation Factor-4A EC 2.7.7.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

128111

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Auteurs

Christian Nilewski (C)

eFFECTOR Therapeutics, 11120 Roselle Street, Suite A, San Diego, CA 92121, United States. Electronic address: nilewski.christian@gene.com.

Theodore D Michels (TD)

eFFECTOR Therapeutics, 11120 Roselle Street, Suite A, San Diego, CA 92121, United States.

Garrick K Packard (GK)

eFFECTOR Therapeutics, 11120 Roselle Street, Suite A, San Diego, CA 92121, United States.

Alan X Xiang (AX)

eFFECTOR Therapeutics, 11120 Roselle Street, Suite A, San Diego, CA 92121, United States.

Paul A Sprengeler (PA)

eFFECTOR Therapeutics, 11120 Roselle Street, Suite A, San Diego, CA 92121, United States.

Boreth Eam (B)

eFFECTOR Therapeutics, 11120 Roselle Street, Suite A, San Diego, CA 92121, United States.

Sarah Fish (S)

eFFECTOR Therapeutics, 11120 Roselle Street, Suite A, San Diego, CA 92121, United States.

Peggy A Thompson (PA)

eFFECTOR Therapeutics, 11120 Roselle Street, Suite A, San Diego, CA 92121, United States.

Christopher J Wegerski (CJ)

eFFECTOR Therapeutics, 11120 Roselle Street, Suite A, San Diego, CA 92121, United States.

Andres Nevarez (A)

eFFECTOR Therapeutics, 11120 Roselle Street, Suite A, San Diego, CA 92121, United States.

Jeff Clarine (J)

eFFECTOR Therapeutics, 11120 Roselle Street, Suite A, San Diego, CA 92121, United States.

Samuel Sperry (S)

eFFECTOR Therapeutics, 11120 Roselle Street, Suite A, San Diego, CA 92121, United States.

Justin T Ernst (JT)

eFFECTOR Therapeutics, 11120 Roselle Street, Suite A, San Diego, CA 92121, United States.

Siegfried H Reich (SH)

eFFECTOR Therapeutics, 11120 Roselle Street, Suite A, San Diego, CA 92121, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH